Institut de recherches cliniques de Montréal
Montreal, Quebec, H2W 1R7, Canada
NCT Number: NCT01930110
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormones: insulin and glucagon.
The objective is to compare the efficacy of single-hormone closed-loop strategy and dual-hormone closed-loop strategy at regulating glucose levels during continuous exercise and interval exercise.
The investigator hypothesized that dual-hormone closed-loop strategy is superior to single-hormone closed-loop strategy in regulating glucose levels during exercise periods.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Montreal, Quebec, H2W 1R7, Canada
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormones: insulin and glucagon.
We aim to conduct a randomized two-way cross-over trial comparing single-hormone closed-loop strategy and dual-hormone closed-loop strategy to compare the two interventions during exercise periods in adults with type 1 diabetes. A moderate intensity exercise will be performed for 60 minutes at 60% of the maximum oxygen consumption (VO2max). A high intensity exercise will be 40 minutes of interval training. The interval training will be preceded by a 10 minutes warm-up and followed by a 10 minutes cool down.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
Time frame: 18:00 hours to 19:30 hours
Time frame: 18:00 to 19:30 hours or 18:00 to 19:10 depending on the exercise performed
Difference between glucose levels at the beginning of the exercise and the lowest glucose level from the start of the exercise until 30 minutes after exercise).
Time frame: 15:30 hours to 19:30 hours
Time frame: 15:30 hours to 19:30 hours
Time frame: 15:30 hours to 19:30 hours
Time frame: 18:00 to 19:30
Time frame: 15:30 hours to 19:30 hours
Time frame: 18:00 to 19:00
Time frame: 15:30 to 19:30
Institut de Recherches Cliniques de Montreal
Other
An Open-label, Randomized, Cross-over Study to Compare the Efficacy of Single-hormone Closed-loop Strategy and Dual-hormone Closed-loop Strategy at Regulating Glucose Levels During Continuous Exercise and Interval Exercise in Adults With Type-1 Diabetes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04614168
Autoimmune Diseases, Diabetes Mellitus
Edinburgh, United Kingdom
View Trial DetailsNCT02846831
Autoimmune Diseases, Diabetes Mellitus
Montreal, Quebec, Canada
View Trial DetailsNCT02855307
Autoimmune Diseases, Behavior
Montreal, Quebec, Canada
View Trial DetailsNCT00811317
Autoimmune Diseases, Diabetes Mellitus
Boston, Massachusetts, United States
View Trial Details